Alkermes targets $310M-$340M adjusted EBITDA amid LYBALVI growth and orexin pipeline expansion
Q4 2024 Management View CEO Richard Pops highlighted 2024 as a transformative year focused on profitability and pipeline development, achieving over $1.5 billion in revenue and $450 million in EBITDA ...
Alkermes' Q4 Earnings & Revenues Surpass Estimates, Stock Up
ALKS reports better-than-expected fourth-quarter 2024 results. Net sales of proprietary products increase year over year. Shares rise.
Hosted on MSN9mon
Will Alkermes' (ALKS) Proprietary Drugs Aid Amid Competition?
Alkermes plc ALKS has made steady progress with its portfolio of proprietary products — Vivitrol (alcohol and opioid dependence), Aristada (schizophrenia) and Lybalvi (schizophrenia and bipolar ...
Alkermes PLC (ALKS) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and Debt-Free Milestone
Alkermes PLC (ALKS) reports over $1.5 billion in revenue, retires all debt, and outlines strategic plans for 2025 amidst ...
CNN1y
Alkermes Public Limited Company
Its proprietary products include ARISTADA, ARISTADA INITIO, LYBALVI, and VIVITROL. The company was founded in 1987 and is headquartered in Dublin, Ireland.